10-Q · May 7, 2026
Cadrenal Therapeutics, Inc. reported significant financial challenges in Q4 2026, with a complete lack of revenue alongside a net loss of $2.5 million, demonstrating a continued decline in performance. Management…
Earnings analysis · 10-Q
CVKD earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Cadrenal’s Q2 2026 EPS loss improved to $1.14 from $1.87 year over year, while operating expenses fell to $3.3 million from $3.7 million. However, the filing emphasizes severe liquidity constraints: the company has an…
Read full summary
Cadrenal’s Q2 2026 EPS loss improved to $1.14 from $1.87 year over year, while operating expenses fell to $3.3 million from $3.7 million. However, the filing emphasizes severe liquidity constraints: the company has an accumulated deficit of $44.8 million, a six-month net loss of $5.8 million, and says existing cash will not fund anticipated needs for the next 12 months. Management has pivoted toward partnerships and out-licensing, but the going-concern uncertainty, dependence on additional financing and fragile Nasdaq compliance outweigh the expense and EPS improvements.
Reported figures
- Earnings per share
- $-1.14
What stood out
-
EPS loss narrowed year over year
Q2 2026 diluted EPS was a loss of $1.14, improving from a loss of $1.87 in Q2 2025, a $0.73 year-over-year improvement.
-
Operating expenses decreased
Operating expenses declined to $3.3 million from $3.7 million in the prior-year quarter, a reduction of $0.4 million, or approximately 11%.
-
Cash runway extends through Q1 2027
Approximately $4.2 million of cash and cash equivalents is expected to fund operations through Q1 2027.
-
Warrant exercise provided liquidity
The company received $2.3 million of net proceeds from the exercise of Existing Warrants on April 1, 2026.
-
Strategy pivots toward partnerships
Management formally pivoted from independent late-stage clinical development to an out-licensing, portfolio monetization and corporate partnership model because it lacks resources to independently fund Phase 3 progression.
-
Disclosure controls remained effective
The company stated that its disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, with no changes in internal control that materially affected or were reasonably likely to materially affect reporting controls during the quarter.
What to watch
-
Going-concern liquidity risk
The filing reports an accumulated deficit of approximately $44.8 million and a net loss of approximately $5.8 million for the six months ended June 30, 2026. Management states existing cash will not be sufficient for anticipated requirements over the next 12 months, creating substantial doubt about the company’s ability to continue as a going concern.
-
Nasdaq listing compliance remains fragile
Stockholders’ equity was $1.8 million as of March 31, 2026, below Nasdaq’s $2.5 million minimum requirement; although the company believes $2.3 million of warrant-exercise proceeds restored compliance, Nasdaq will continue monitoring compliance and may initiate delisting proceedings if compliance is not evidenced in the next periodic report.
-
PIPE restrictions may limit financing
The company’s PIPE-related restrictions limit certain Common Stock or common-stock-equivalent issuances and variable-rate transactions for periods following the applicable effective date, including a one-year restriction on variable-rate transactions and only a limited exception for ATM sales beginning 60 days after effectiveness. These restrictions could constrain financing while the company requires substantial additional capital.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that approximately $4.2 million of cash and cash equivalents is expected to fund operations through Q1 2027, but existing resources are insufficient to advance candidates to clinical-trial readiness or conduct trials.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.